Navigation Links
Novagali Pharma Completes a EUR15 Million Fund Raising
Date:9/26/2008

EVRY, France, September 26 /PRNewswire/ -- Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured EUR15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:

- The commercialization in France and abroad of its first

marketable product, Cationorm(R), indicated for the treatment of dry eye

symptoms,

- The development of its flagship products: Vekacia(R) (Vernal

keratoconjunctivitis), Cyclokat(R) (Dry eye), Nova21027 (Glaucoma) and

Cortiject(R) (Diabetic macular edema), and particularly for Cyclokat(R)

the phase III clinical study now in course in Europe and the one

initiated in the United States during the third quarter of 2008 as well

as the phase I finalization in patient with Cortiject(R) started in

April 2008 in the United States.

Jerome Martinez, Novagali Pharma Chief Executive Officer, says: "The total amount of this fund rising strengthens once again our investors confidence to our development strategy, our products and our technological approach. This new source of financing will help us to carry on our company development".

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).


'/>"/>
SOURCE Novagali Pharma SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novagali Pharma Announces the Launch of Cationorm(R)
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
6. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
9. AIT Laboratories Expands Pharma Services
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
(Date:1/19/2017)...  Market Research Future has a half cooked research report on ... growing rapidly and expected to reach USD 450 Million by the ... ... has been assessed as a swiftly growing market and expected that ... coming future. There has been a tremendous growth in the prevalence ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
Breaking Biology Technology:
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):